Patient Experiences After Aborted Cancer Surgery: A Qualitative Study
- PMID: 37540329
- DOI: 10.1245/s10434-023-14046-6
Patient Experiences After Aborted Cancer Surgery: A Qualitative Study
Abstract
Background: Surgical resection is a necessary component of curative-intent treatment for most solid-organ cancers but is occasionally aborted, most often due to occult metastatic disease or unanticipated unresectability. Despite its frequency, little research has been performed on the experiences, care needs, and treatment preferences of patients who experience an aborted cancer surgery.
Methods: Semistructured interviews of patients who had previously experienced an aborted cancer surgery were conducted, focusing on their recalled experiences and stated preferences. All interviews were audio recorded, transcribed, and coded by two independent researchers by using NVivo 12. An integrative approach to qualitative analysis was used-both inductive and deductive methods-and iteratively identifying themes until saturation was reached.
Results: Fifteen patients with an aborted cancer surgery participated in the interviews. Cancer types included pancreatic (n = 9), cholangiocarcinoma (n = 3), hepatocellular carcinoma (n = 1), gallbladder (n = 1), and neuroendocrine (n = 1). The most common reasons for aborting surgery included local tumor unresectability (n = 8) and occult metastatic disease (n = 7). Five subthemes that characterized the patient experience following an aborted cancer surgery emerged, including physical symptoms, emotional responses, impact on social and life factors, coping mechanisms, and support received.
Conclusions: This qualitative study characterizes the impact of aborted cancer surgery on multiple domains of quality of life: physical, emotional, social, and existential. These results highlight the importance of developing patient-centered interventions that focus on enhancing quality of life after aborted cancer surgery.
© 2023. Society of Surgical Oncology.
Comment in
-
ASO Author Reflections: Understanding and Addressing Patient Care Needs after Aborted Cancer Surgery.Ann Surg Oncol. 2023 Dec;30(13):8105-8106. doi: 10.1245/s10434-023-14101-2. Epub 2023 Aug 12. Ann Surg Oncol. 2023. PMID: 37573283 No abstract available.
References
-
- Azari FS, Vollmer CM Jr, Roses RE, et al. A contemporary analysis of palliative procedures in aborted pancreatoduodenectomy: morbidity, mortality, and impact on future therapy. Surgery. 2020;168(6):1026–31. https://doi.org/10.1016/j.surg.2020.06.041 . - DOI - PubMed
-
- Shah MM, Ajay PS, Meltzer RS, et al. The aborted whipple: why, and what happens next? J Surg Oncol. 2022;125(4):642–5. https://doi.org/10.1002/jso.26781 . - DOI - PubMed
-
- Beal EW, Ahmed A, Grotz T, et al. Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am J Surg. 2020;219(3):478–83. https://doi.org/10.1016/j.amjsurg.2019.09.017 . - DOI - PubMed
-
- Guzzo TJ, Rogers CG, Deng CY, et al. Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease. BJU Int. 2008;102(11):1539–43. https://doi.org/10.1111/j.1464-410X.2008.07877.x . - DOI - PubMed
-
- Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery. 2008;143(3):366–74. https://doi.org/10.1016/j.surg.2007.10.010 . - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
